Search research articles
Contact Us
Filters
Showing results (501-510 of 521) with videos related to
Page
of 53
Sort By:
The Lancet. Gastroenterology & Hepatology
|
August 6, 2021
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Milind Javle, Sameek Roychowdhury, Robin Kate Kelley, et al.
Biorxiv : the Preprint Server for Biology
|
December 22, 2025
PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer
Sahar F Bannoura, Husain Yar Khan, Amro Aboukameel, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 7, 2024
ALLIANCE A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer
J Alvarez, Q Shi, A Dasari, et al.
Journal of the National Cancer Institute
|
March 20, 2025
Utilizing Patient Input in Rectal Cancer Trial Design
Janet Alvarez, Wini Zambare, Manju George, et al.
Journal for Immunotherapy of Cancer
|
January 11, 2024
<i>CCR5</i> and <i>CCL5</i> gene expression in colorectal cancer: comprehensive profiling and clinical value
Francesca Battaglin, Yasmine Baca, Joshua Millstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2013
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study
Philip J Johnson, Shukui Qin, Joong-Won Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 29, 2017
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle, Maeve Lowery, Rachna T Shroff, et al.
Biorxiv : the Preprint Server for Biology
|
January 23, 2026
Genomic and Transcriptomic Landscapes of MEN1-Wild-Type Low-Grade Metastatic Pancreatic NETs Uncover Key Oncogenic Drivers and Targetable Pathways
Md Hafiz Uddin, Zaid Mahdi, Irfana Muqbil, et al.
JCO Precision Oncology
|
March 6, 2025
Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group
Lakshmi Rajdev, Gentry G King, Christopher H Lieu, et al.
Biorxiv : the Preprint Server for Biology
|
December 15, 2025
Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma
Husain Yar Khan, Mohammed Najeeb Al Hallak, Amro Aboukameel, et al.
Page
of 53
Search research articles
Search
Showing results (501-510 of 521) with videos related to
Sort By:
Page
of 53
The Lancet. Gastroenterology & Hepatology
|
August 6, 2021
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Milind Javle, Sameek Roychowdhury, Robin Kate Kelley, et al.
Biorxiv : the Preprint Server for Biology
|
December 22, 2025
PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer
Sahar F Bannoura, Husain Yar Khan, Amro Aboukameel, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 7, 2024
ALLIANCE A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer
J Alvarez, Q Shi, A Dasari, et al.
Journal of the National Cancer Institute
|
March 20, 2025
Utilizing Patient Input in Rectal Cancer Trial Design
Janet Alvarez, Wini Zambare, Manju George, et al.
Journal for Immunotherapy of Cancer
|
January 11, 2024
<i>CCR5</i> and <i>CCL5</i> gene expression in colorectal cancer: comprehensive profiling and clinical value
Francesca Battaglin, Yasmine Baca, Joshua Millstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2013
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study
Philip J Johnson, Shukui Qin, Joong-Won Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 29, 2017
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle, Maeve Lowery, Rachna T Shroff, et al.
Biorxiv : the Preprint Server for Biology
|
January 23, 2026
Genomic and Transcriptomic Landscapes of MEN1-Wild-Type Low-Grade Metastatic Pancreatic NETs Uncover Key Oncogenic Drivers and Targetable Pathways
Md Hafiz Uddin, Zaid Mahdi, Irfana Muqbil, et al.
JCO Precision Oncology
|
March 6, 2025
Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group
Lakshmi Rajdev, Gentry G King, Christopher H Lieu, et al.
Biorxiv : the Preprint Server for Biology
|
December 15, 2025
Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma
Husain Yar Khan, Mohammed Najeeb Al Hallak, Amro Aboukameel, et al.
Page
of 53